Each compound has different characteristics, and only by selecting the characteristics of the compound suitable for a specific situation can the compound be applied on a large scale. 76176-87-9, name is Thiomorpholine-1-oxide hydrochloride. This compound has unique chemical properties. The synthetic route is as follows. 76176-87-9
To a suspension of Intermediate 41 (68.4 mg, 0.146 mmol, 1.0 eq) in anhydrous CH2CI2 (3 mL) was added 1-oxide thiomorpholine hydrochloride (45.6 mg, 0.293 mmol, 2.0 eq) and sodium acetate (24.0 mg, 0.293 mmol, 2.0 eq) and the resulting suspension was stirred at 42 C for 6 h. After cooling to rt, NaBH(OAc)3(62.1 mg, 0.293 mmol, 2.0 eq) was added and the reaction mixture was stirred at rt for 16 h. Additional portions of sodium acetate (12.0 mg, 0.147 mmol, 1.0 eq), 1-oxide thiomorpholine hydrochloride (22.8 mg, 0.147 mmol, 1.0 eq) and NaBH(OAc)3 (31.1 mg, 0.147 mmol, 1.0 eq) were added and the reaction was stirred at 40C for 18 h. Upon cooling to rt, the reaction was quenched with 1 Maqueous NaOH (5 mL) then poured into H20 (15 mL) and extracted with CH2CI2(3 x 15 mL). The combined organic extracts were concentrated in vacuo andpurified by silica gel chromatography using EtOAc/MeOH (1 :0-13:1). The productwas re-dissolved in CH2CI2/MeOH (4:1, 10 mL) and swirled with MP-TMT resin(157 mg, 0.173 mmol) at rt overnight. The solution was filtered and the resinwashed with CH2CI2/MeOH (4:1, 100 mL). The filtrate was concentrated in vacuoand purified a second time by silica gel column chromatography with CH2CI2/MeOH (1:0-12:1) to yield Example S as a white solid (37.6 mg, 45%).1H NMR (300MHz, DMSO-d5) oH. 12.47 (5, 1H), 8.54-8.67 (m, 2H), 8.28 (dd, J=7.4, 0.8 Hz, 1H), 7.98 (5, 1H), 7.64 (d, J=8.1 Hz, 1H), 7.40-7.52 (m, 1H), 4.08-4.19 (m, 4H), 3.81-3.92 (m, 6H), 2.86-3.02 (m, 4H), 2.68-2.80 (m, 4H).19F NMR (282MHz, DMSO-d5) 0F. -58.8 (5, 3F).MS (ESj 571.0 (100%, [M+H]j.
While traditionally a conservative industry, chemical producers will need to modernize their PR strategies to stay relevant. 76176-87-9, we look forward to future research findings about .
Reference£º
Patent; KARUS THERAPEUTICS LTD; SHUTTLEWORTH, Stephen Joseph; SILVA, Franck Alexandre; CECIL, Alexander Richard Liam; ALEXANDER, Rikki Peter; GATLAND, Alice Elizabeth; FINNEMORE, Daniel John; (123 pag.)WO2017/29521; (2017); A1;,
Thiomorpholine – Wikipedia
Thiomorpholine | C4H9NS – PubChem